Skip to main content
Top
Published in: Supportive Care in Cancer 8/2016

Open Access 01-08-2016 | Original Article

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer

Authors: Charles Cleeland, Roger von Moos, Mark S. Walker, Yuanyuan Wang, Jianqing Gao, Mariana Chavez-MacGregor, Alexander Liede, Jorge Arellano, Arun Balakumaran, Yi Qian

Published in: Supportive Care in Cancer | Issue 8/2016

Login to get access

Abstract

Purpose

Women with breast cancer frequently develop painful bone metastases. This retrospective study was designed to longitudinally characterize patterns of patient-reported symptoms among patients with breast cancer relative to the diagnosis of bone metastases.

Methods

Patient records were identified from the Oncology Services Comprehensive Electronic Records (OSCER) database which includes outpatient oncology practices across the USA. Symptom burden was assessed by Patient Care Monitor (PCM) assessments, which are administered as part of routine care in a subset of these practices. Eligible patients were women diagnosed with breast cancer (ICD-9-CM 174.xx) who developed bone metastases (ICD-9-CM 198.5) and had ≥1 PCM assessment between January 2007 and December 2012. The pre-specified endpoint was the occurrence of moderate to severe symptom burden, defined as PCM score ≥4 (0–10 scale).

Results

One thousand one hundred five women (median age, 61) met the eligibility criteria. Worsening of symptoms, particularly fatigue and pain, occurred in the months leading up to the diagnosis of bone metastases. After bone metastases diagnosis, the rate of increase in the proportion of patients experiencing moderate/severe symptoms slowed, but continued to climb during follow-up. Median time to moderate/severe symptoms was 0.9 month for fatigue, 1 month for pain, 2.9 months for trouble sleeping, and 7.7 months for numbness/tingling. Half of the patients received bone-targeted agents after diagnosis of bone metastases.

Conclusions

Symptom burden, especially pain and fatigue, increased both before and after the diagnosis of bone metastases, highlighting the need for proactive monitoring and management of symptoms in breast cancer patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Can Res 12:6243s–6249sCrossRef Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Can Res 12:6243s–6249sCrossRef
2.
go back to reference Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergstrom B (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312CrossRefPubMed Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergstrom B (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312CrossRefPubMed
3.
go back to reference von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K (2013) Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 21:3497–3507CrossRef von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K (2013) Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 21:3497–3507CrossRef
4.
go back to reference Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869–1876CrossRefPubMedPubMedCentral Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869–1876CrossRefPubMedPubMedCentral
5.
go back to reference Chow E, Hruby G, Davis L, Holden L, Schueller T, Wong R, Hayter C, Szumacher E, Loblaw A, Danjoux C (2004) Quality of life after local external beam radiation therapy for symptomatic bone metastases: a prospective evaluation. Support Cancer Ther 1:179–184CrossRefPubMed Chow E, Hruby G, Davis L, Holden L, Schueller T, Wong R, Hayter C, Szumacher E, Loblaw A, Danjoux C (2004) Quality of life after local external beam radiation therapy for symptomatic bone metastases: a prospective evaluation. Support Cancer Ther 1:179–184CrossRefPubMed
6.
go back to reference Cleeland CS (2006) The measurement of pain from metastatic bone disease: capturing the patient’s experience. Clinical Can Res 12:6236s–6242sCrossRef Cleeland CS (2006) The measurement of pain from metastatic bone disease: capturing the patient’s experience. Clinical Can Res 12:6236s–6242sCrossRef
7.
go back to reference Cleeland CS, Zhao F, Chang VT, Sloan JA, O’Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ (2013) The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119:4333–4340CrossRefPubMed Cleeland CS, Zhao F, Chang VT, Sloan JA, O’Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ (2013) The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119:4333–4340CrossRefPubMed
8.
go back to reference Kenne Sarenmalm E, Browall M, Gaston-Johansson F (2014) Symptom burden clusters: a challenge for targeted symptom management. A longitudinal study examining symptom burden clusters in breast cancer. J Pain Symptom Manage 47:731–741CrossRefPubMed Kenne Sarenmalm E, Browall M, Gaston-Johansson F (2014) Symptom burden clusters: a challenge for targeted symptom management. A longitudinal study examining symptom burden clusters in breast cancer. J Pain Symptom Manage 47:731–741CrossRefPubMed
9.
go back to reference Reed E, Simmonds P, Haviland J, Corner J (2012) Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manag 43:747–758CrossRef Reed E, Simmonds P, Haviland J, Corner J (2012) Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manag 43:747–758CrossRef
10.
go back to reference Stanton AL, Wiley JF, Krull JL, Crespi CM, Hammen C, Allen JJ, Barron ML, Jorge A, Weihs KL (2015) Depressive episodes, symptoms, and trajectories in women recently diagnosed with breast cancer. Breast Cancer Res Treat 154:105–115CrossRefPubMed Stanton AL, Wiley JF, Krull JL, Crespi CM, Hammen C, Allen JJ, Barron ML, Jorge A, Weihs KL (2015) Depressive episodes, symptoms, and trajectories in women recently diagnosed with breast cancer. Breast Cancer Res Treat 154:105–115CrossRefPubMed
11.
go back to reference Mendoza TR, Zhao F, Cleeland CS, Wagner LI, Patrick-Miller LJ, Fisch MJ (2013) The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the Eastern Cooperative Oncology Group. Clin Breast Cancer 13:325–334CrossRefPubMedPubMedCentral Mendoza TR, Zhao F, Cleeland CS, Wagner LI, Patrick-Miller LJ, Fisch MJ (2013) The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the Eastern Cooperative Oncology Group. Clin Breast Cancer 13:325–334CrossRefPubMedPubMedCentral
12.
go back to reference Walker MS, Hasan M, Yim YM, Yu E, Stepanski EJ, Schwartzberg LS (2011) Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. Health Qual Life Outcomes 9:46CrossRefPubMedPubMedCentral Walker MS, Hasan M, Yim YM, Yu E, Stepanski EJ, Schwartzberg LS (2011) Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. Health Qual Life Outcomes 9:46CrossRefPubMedPubMedCentral
13.
go back to reference Palesh OG, Collie K, Batiuchok D, Tilston J, Koopman C, Perlis ML, Butler LD, Carlson R, Spiegel D (2007) A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol 75:37–44CrossRefPubMed Palesh OG, Collie K, Batiuchok D, Tilston J, Koopman C, Perlis ML, Butler LD, Carlson R, Spiegel D (2007) A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol 75:37–44CrossRefPubMed
14.
go back to reference Walker MS, Miller PJ, Namjoshi M, Houts AC, Stepanski EJ, Schwartzberg LS (2013) Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases. J Med Econ 16:179–189CrossRefPubMed Walker MS, Miller PJ, Namjoshi M, Houts AC, Stepanski EJ, Schwartzberg LS (2013) Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases. J Med Econ 16:179–189CrossRefPubMed
15.
go back to reference Lau EC, Mowat FS, Kelsh MA, Legg JC, Engel-Nitz NM, Watson HN, Collins HL, Nordyke RJ, Whyte JL (2011) Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data. Clin Epidemiol 3:259–272PubMedPubMedCentral Lau EC, Mowat FS, Kelsh MA, Legg JC, Engel-Nitz NM, Watson HN, Collins HL, Nordyke RJ, Whyte JL (2011) Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data. Clin Epidemiol 3:259–272PubMedPubMedCentral
16.
go back to reference Abernethy AP, Zafar SY, Uronis H, Wheeler JL, Coan A, Rowe K, Shelby RA, Fowler R, Herndon JE 2nd (2010) Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. J Pain Symptom Manag 40:545–558CrossRef Abernethy AP, Zafar SY, Uronis H, Wheeler JL, Coan A, Rowe K, Shelby RA, Fowler R, Herndon JE 2nd (2010) Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. J Pain Symptom Manag 40:545–558CrossRef
17.
go back to reference Fortner B, Baldwin S, Schwartzberg L, Houts AC (2006) Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manag 31:207–214CrossRef Fortner B, Baldwin S, Schwartzberg L, Houts AC (2006) Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manag 31:207–214CrossRef
18.
go back to reference Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC (2003) The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manag 26:1077–1092CrossRef Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC (2003) The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manag 26:1077–1092CrossRef
19.
go back to reference Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K (2011) Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol 9:72–78CrossRefPubMed Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K (2011) Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol 9:72–78CrossRefPubMed
20.
go back to reference Ancoli-Israel S, Liu L, Rissling M, Natarajan L, Neikrug AB, Palmer BW, Mills PJ, Parker BA, Sadler GR, Maglione J (2014) Sleep, fatigue, depression, and circadian activity rhythms in women with breast cancer before and after treatment: a 1-year longitudinal study. Support Care Cancer 22:2535–2545CrossRefPubMedPubMedCentral Ancoli-Israel S, Liu L, Rissling M, Natarajan L, Neikrug AB, Palmer BW, Mills PJ, Parker BA, Sadler GR, Maglione J (2014) Sleep, fatigue, depression, and circadian activity rhythms in women with breast cancer before and after treatment: a 1-year longitudinal study. Support Care Cancer 22:2535–2545CrossRefPubMedPubMedCentral
21.
go back to reference Avis NE, Levine BJ, Case LD, Naftalis EZ, Van Zee KJ (2015) Trajectories of depressive symptoms following breast cancer diagnosis. Cancer Epidemiol Biomark Prev 24:1789–1795CrossRef Avis NE, Levine BJ, Case LD, Naftalis EZ, Van Zee KJ (2015) Trajectories of depressive symptoms following breast cancer diagnosis. Cancer Epidemiol Biomark Prev 24:1789–1795CrossRef
22.
go back to reference Cheung WY, Barmala N, Zarinehbaf S, Rodin G, Le LW, Zimmermann C (2009) The association of physical and psychological symptom burden with time to death among palliative cancer outpatients. J Pain Symptom Manag 37:297–304CrossRef Cheung WY, Barmala N, Zarinehbaf S, Rodin G, Le LW, Zimmermann C (2009) The association of physical and psychological symptom burden with time to death among palliative cancer outpatients. J Pain Symptom Manag 37:297–304CrossRef
23.
go back to reference Fiszer C, Dolbeault S, Sultan S, Bredart A (2014) Prevalence, intensity, and predictors of the supportive care needs of women diagnosed with breast cancer: a systematic review. Psychooncology 23:361–374CrossRefPubMed Fiszer C, Dolbeault S, Sultan S, Bredart A (2014) Prevalence, intensity, and predictors of the supportive care needs of women diagnosed with breast cancer: a systematic review. Psychooncology 23:361–374CrossRefPubMed
24.
go back to reference Huang HP, Chen ML, Liang J, Miaskowski C (2014) Changes in and predictors of severity of fatigue in women with breast cancer: a longitudinal study. Int J Nurs Stud 51:582–592CrossRefPubMed Huang HP, Chen ML, Liang J, Miaskowski C (2014) Changes in and predictors of severity of fatigue in women with breast cancer: a longitudinal study. Int J Nurs Stud 51:582–592CrossRefPubMed
25.
go back to reference Jones JM, Olson K, Catton P, Catton CN, Fleshner NE, Krzyzanowska MK, McCready DR, Wong RK, Jiang H, Howell D (2015) Cancer-related fatigue and associated disability in post-treatment cancer survivors. J Cancer Surviv. doi:10.1007/s11764-015-0450-2 Jones JM, Olson K, Catton P, Catton CN, Fleshner NE, Krzyzanowska MK, McCready DR, Wong RK, Jiang H, Howell D (2015) Cancer-related fatigue and associated disability in post-treatment cancer survivors. J Cancer Surviv. doi:10.​1007/​s11764-015-0450-2
26.
go back to reference Sanford SD, Beaumont JL, Butt Z, Sweet JJ, Cella D, Wagner LI (2014) Prospective longitudinal evaluation of a symptom cluster in breast cancer. J Pain Symptom Manag 47:721–730CrossRef Sanford SD, Beaumont JL, Butt Z, Sweet JJ, Cella D, Wagner LI (2014) Prospective longitudinal evaluation of a symptom cluster in breast cancer. J Pain Symptom Manag 47:721–730CrossRef
27.
go back to reference Seow H, Barbera L, Sutradhar R, Howell D, Dudgeon D, Atzema C, Liu Y, Husain A, Sussman J, Earle C (2011) Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 29:1151–1158CrossRefPubMed Seow H, Barbera L, Sutradhar R, Howell D, Dudgeon D, Atzema C, Liu Y, Husain A, Sussman J, Earle C (2011) Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 29:1151–1158CrossRefPubMed
28.
go back to reference Trudel-Fitzgerald C, Savard J, Ivers H (2013) Evolution of cancer-related symptoms over an 18-month period. J Pain Symptom Manag 45:1007–1018CrossRef Trudel-Fitzgerald C, Savard J, Ivers H (2013) Evolution of cancer-related symptoms over an 18-month period. J Pain Symptom Manag 45:1007–1018CrossRef
29.
go back to reference Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS (2012) Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30:1980–1988CrossRefPubMedPubMedCentral Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS (2012) Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30:1980–1988CrossRefPubMedPubMedCentral
30.
go back to reference Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K (2013) Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 119:832–838CrossRefPubMed Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K (2013) Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 119:832–838CrossRefPubMed
31.
go back to reference Cai B, Nickman NA, Gaffney DK (2013) The role of palliative external beam radiation therapy in boney metastases pain management. J Pain Palliat Care Pharmacother 27:28–34CrossRefPubMed Cai B, Nickman NA, Gaffney DK (2013) The role of palliative external beam radiation therapy in boney metastases pain management. J Pain Palliat Care Pharmacother 27:28–34CrossRefPubMed
32.
go back to reference Kremer R, Gagnon B, Meguerditchian AN, Nadeau L, Mayo N (2014) Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study. J Natl Cancer Inst 106 Kremer R, Gagnon B, Meguerditchian AN, Nadeau L, Mayo N (2014) Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study. J Natl Cancer Inst 106
33.
go back to reference Towle A, Godolphin W (2013) Patients as educators: interprofessional learning for patient-centred care. Med Teach 35:219–225CrossRefPubMed Towle A, Godolphin W (2013) Patients as educators: interprofessional learning for patient-centred care. Med Teach 35:219–225CrossRefPubMed
Metadata
Title
Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
Authors
Charles Cleeland
Roger von Moos
Mark S. Walker
Yuanyuan Wang
Jianqing Gao
Mariana Chavez-MacGregor
Alexander Liede
Jorge Arellano
Arun Balakumaran
Yi Qian
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 8/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3154-x

Other articles of this Issue 8/2016

Supportive Care in Cancer 8/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine